Concise Review: Making and Using Clinically Compliant Pluripotent Stem Cell Lines
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
The field of pluripotent stem cells (PSCs) is in a state of dynamic flux driven by significant advances in the derivation of specific phenotypes from embryonic stem cells, breakthroughs in somatic cell nuclear transfer, and dramatic improvements in generating induced PSCs using zero footprint methods. Spurred by these technological advances, companies have begun to plan clinical studies using human PSC derivatives manufactured in current Good Manufacturing Practice-compliant conditions. In the present review, we discuss the challenges in making these biological products, starting from tissue sourcing to the processes involved in manufacture, storage, and distribution. Additional challenges exist to meeting the regulatory requirements and keeping costs affordable. A model is described that has been proposed by the U.S. National Institutes of Health for reducing the costs and permitting flexibility and innovation by individual investigators. This model, combined with small adjustments in the regulatory processes tailored to address the unique properties of PSCs, has the potential of significantly accelerating the implementation of PSC-based cell therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bock, C., Kiskinis, E., Verstappen, G., Gu, H., Boulting, G., Smith, Z. D., Ziller, M., Croft, G. F., Amoroso, M. W., Oakley, D. H., et al. (2011) · Cell · doi:10.1016/j.cell.2010.12.032 · Cited by 1,009
Genetic Background Drives Transcriptional Variation in Human Induced Pluripotent Stem Cells
Rouhani, F., Kumasaka, N., de Brito, M. C., Bradley, A., Vallier, L., & Gaffney, D. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004432 · Cited by 294
Toward the development of a global induced pluripotent stem cell library
Turner, M., Leslie, S., Martin, N. G., Peschanski, M., Rao, M., Taylor, C. J., Trounson, A., Turner, D., Yamanaka, S., & Wilmut, I. (2013) · Cell stem cell · doi:10.1016/j.stem.2013.08.003 · Cited by 245
Self-citation
Cited by
Baghbaderani, B. A., Tian, X., Neo, B. H., Burkall, A., Dimezzo, T., Sierra, G., Zeng, X., Warren, K., Kovarcik, D. P., Fellner, T., et al. (2015) · Stem Cell Reports · doi:10.1016/j.stemcr.2015.08.015 · Cited by 212
“…Asteris, Ocata (formerly known as Advanced Cell Technology), Biotime, Viacyte, and J&J have developed products from ESCs, several have initiated early-stage clinical trials (Carpenter and Rao, 2015), and several patients have been treatedwith no deleterious side effects (Schwartz et al., 2012).”
BackgroundSelf-citationAzuma, K., & Yamanaka, S. (2016) · Regenerative Therapy · doi:10.1016/j.reth.2016.01.009 · Cited by 63
Truong, V., Viken, K., Geng, Z., Barkan, S., Johnson, B., Ebeling, M. C., Montezuma, S. R., Ferrington, D. A., & Dutton, J. R. (2021) · SLAS TECHNOLOGY · doi:10.1177/2472630320972110 · Cited by 30
Metadata
- Authors
- Carpenter, M. K., & Rao, M. S.
- Venue
- Stem Cells Translational Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-02-26
- Volume
- 4
- Issue
- 4
- Pages
- 381-388
- ISSN
- 2157-6564 (ISSN-L)
- 2157-6580
- OpenAlex
- W2105543627
- Cited by
- 47
- References
- 3
- FWCI
- 2.06
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.